Kalaris Therapeutics (KLRS) Price & Analysis

Compare

365 Followers

KLRS Stock Chart & Stats

$5.45

Market closed

$5.45

Day’s Range― - ―

52-Week Range$2.14 - $12.90

Previous CloseN/A

VolumeN/A

Average Volume (3M)136.22K

Market Cap

$107.96M

Enterprise Value$32.64M

Total Cash (Recent Filing)$77.00M

Total Debt (Recent Filing)$1.54M

Price to Earnings (P/E)―

Beta0.65

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-11.75

Shares Outstanding18,702,417

10 Day Avg. Volume189,046

30 Day Avg. Volume136,224

Financial Highlights & Ratios

PEG Ratio-0.13

Price to Book (P/B)0.40

Price to Sales (P/S)0.00

P/FCF Ratio-0.67

Enterprise Value/Market Cap0.30

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-1.02

Forecast

1Y Price Target

$21.00

Price Target Upside285.32% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-3.22

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsKalaris initiated a Phase Ib/II dose-finding, multiple-ascending dose (MAD) clinical trial designed to evaluate multiple dose levels of TH103 in up to 80 patients with neovascular age-related macular degeneration.

LeadershipKalaris recently expanded its leadership team with the hiring of Chief Financial Officer Matthew Gall, who brings over 20 years of corporate finance experience, including business development transactions and financial operations and strategy for small and large organizations.

PartnershipsKalaris announced it had selected KBI Biopharma, based in North Carolina, as the contract development and manufacturing organization for manufacturing the clinical supply of TH103.

Bears Say

Data InterpretationPhase I data in neovascular AMD can be challenging to interpret due to the heterogeneity of the disease, small sample sizes, and early nature of the data.

Kalaris Therapeutics News

Kalaris Therapeutics reports Q3 EPS (64c), consensus (61c)

“The third quarter marked an important inflection point for Kalaris,” said Andrew Oxtoby, Chief Executive Officer of Kalaris...

22d ago

KLRS

Kalaris Therapeutics Reports Q3 2025 Financial Progress

Kalaris Therapeutics, Inc. ( ($KLRS) ) has released its Q3 earnings. Here is a breakdown of the information...

20d ago

KLRS

Positive Outlook for Kalaris Therapeutics: Buy Rating Affirmed Amid Promising Clinical Developments

William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on KLRS stock, giving a Buy rating...

22d ago

KLRS

Kalaris Therapeutics Appoints New CFO Matthew Gall

Kalaris Therapeutics ( ($KLRS) ) just unveiled an announcement. Kalaris Therapeutics, Inc. announced the appointment of Matthew Gall...

1M ago

KLRS

Kalaris Therapeutics appoints Gall as Chief Financial Officer

Kalaris Therapeutics (KLRS) announced the appointment of Matthew Gall, MBA, as Chief Financial Officer. Gall most recently served...

1M ago

KLRS

Kalaris Therapeutics initiated with an Outperform at Citizens JMP

Citizens JMP initiated coverage of Kalaris Therapeutics (KLRS) with an Outperform rating and $20 price target The company...

1M ago

KLRS

Optimistic Buy Rating for Kalaris Therapeutics: Advancements in TH103 for nAMD

William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on KLRS stock, giving a Buy rating...

3M ago

KLRS

Kalaris Therapeutics now enrolling Phase 1b/2 MAD study of TH103

Kalaris Therapeutics (KLRS) announced that it is now enrolling a Phase 1b/2 multiple ascending dose, MAD, study of...

3M ago

KLRS

Kalaris Therapeutics initiated with a Strong Buy at Raymond James

Raymond James analyst Christopher Raymond initiated coverage of Kalaris Therapeutics (KLRS) with a Strong Buy rating and $23...

3M ago

KLRS

Kalaris Therapeutics Reports Q2 2025 Financial Results

Kalaris Therapeutics, Inc. ( ($KLRS) ) has released its Q2 earnings. Here is a breakdown of the information...

4M ago

KLRS

Kalaris Therapeutics Elects New Directors at Annual Meeting

Kalaris Therapeutics ( ($KLRS) ) just unveiled an announcement. At the 2025 Annual Meeting of Stockholders held on...

4M ago

KLRS

Kalaris Therapeutics reports Q2 EPS (61c), consensus (52c)

“We continued to enroll treatment-naive nAMD patients in our open-label Phase 1 clinical trial of TH103 in the...

4M ago

KLRS

Kalaris Therapeutics assumed with a Neutral at Piper Sandler

Piper Sandler analyst Biren Amin assumed coverage of Kalaris Therapeutics (KLRS) with a Neutral rating and $3 price...

4M ago

KLRS

Cautious Hold on Kalaris Therapeutics: Awaiting Key Data on TH103’s Potential in Wet AMD

Biren Amin, an analyst from Piper Sandler, maintained the Hold rating on Kalaris Therapeutics. The associated price target...

4M ago

KLRS

KLRS FAQ

What was Kalaris Therapeutics’s price range in the past 12 months?

Kalaris Therapeutics lowest stock price was $2.14 and its highest was $12.90 in the past 12 months.

What is Kalaris Therapeutics’s market cap?

Kalaris Therapeutics’s market cap is $107.96M.

When is Kalaris Therapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Kalaris Therapeutics’s earnings last quarter?

Kalaris Therapeutics released its earnings results on Aug 13, 2025. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.46 by -$0.15.

Is Kalaris Therapeutics overvalued?

According to Wall Street analysts Kalaris Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kalaris Therapeutics pay dividends?

Kalaris Therapeutics does not currently pay dividends.

What is Kalaris Therapeutics’s EPS estimate?

Kalaris Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kalaris Therapeutics have?

Kalaris Therapeutics has 18,702,417 shares outstanding.

What happened to Kalaris Therapeutics’s price movement after its last earnings report?

Kalaris Therapeutics reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.46. Following the earnings report the stock price went down -2.17%.

Which hedge fund is a major shareholder of Kalaris Therapeutics?

Currently, no hedge funds are holding shares in KLRS

Kalaris Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-63.45%

Trailing 12-Months

Asset Growth

-33.75%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Kalaris Therapeutics

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

Kalaris Therapeutics (KLRS) Earnings & Revenues

Historic Earnings Reports

KLRS Stock 12 Month Forecast

Average Price Target

$21.00

▲(285.32% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","24":"$24","6.75":"$6.75","12.5":"$12.5","18.25":"$18.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$23.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6.75,12.5,18.25,24],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.03,6.412307692307692,7.794615384615385,9.176923076923078,10.55923076923077,11.94153846153846,13.323846153846155,14.706153846153846,16.088461538461537,17.470769230769232,18.853076923076923,20.235384615384614,21.61769230769231,{"y":23,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.03,6.258461538461539,7.486923076923077,8.715384615384615,9.943846153846152,11.17230769230769,12.40076923076923,13.62923076923077,14.857692307692307,16.086153846153845,17.314615384615383,18.54307692307692,19.77153846153846,{"y":21,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.03,6.181538461538461,7.3330769230769235,8.484615384615385,9.636153846153846,10.787692307692307,11.939230769230768,13.09076923076923,14.24230769230769,15.393846153846152,16.545384615384613,17.696923076923074,18.84846153846154,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.2,"date":1709251200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":18.63,"date":1714521600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":18.4,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":21.93,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.66,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.8,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.58,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.07,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.03,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >